JS213

JS213 is an investigational bispecific antibody fusion protein developed by Junshi Biosciences for the treatment of advanced malignant tumors. It is designed to simultaneously target the Programmed Cell Death Protein 1 (PD-1) receptor and the Interleukin-2 (IL-2) signaling pathway. By blocking the PD-1 checkpoint, JS213 alleviates the inhibition of T-cell activation, while the IL-2 component acts as a cytokine agonist to promote the proliferation and effector function of T cells and natural killer (NK) cells. This dual immunomodulatory approach aims to overcome the immunosuppressive tumor microenvironment and enhance anti-tumor efficacy compared to monotherapy. As of 2025, the drug is in Phase I/II clinical development.

Other names

PD-1/IL-2 bifunctional antibody fusion proteinPD-1 x IL-2 bispecific antibody fusion proteinPD1 x IL-2 bispecific antibody fusion proteinPD 1 x IL-2 bispecific antibody fusion protein